Sanofi India Ltd
Sanofi India is engaged in Business of Manufacture and sale of pharmaceutical products.
- Market Cap ₹ 19,021 Cr.
- Current Price ₹ 8,259
- High / Low ₹ 9,380 / 5,330
- Stock P/E 32.2
- Book Value ₹ 441
- Dividend Yield 2.02 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Stock is trading at 18.7 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Multinational
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Dec 2023 | |
---|---|
2,851 | |
2,047 | |
Operating Profit | 804 |
OPM % | 28% |
83 | |
Interest | 2 |
Depreciation | 40 |
Profit before tax | 846 |
Tax % | 29% |
603 | |
EPS in Rs | 261.78 |
Dividend Payout % | 64% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | % |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | % |
Stock Price CAGR | |
---|---|
10 Years: | 10% |
5 Years: | 7% |
3 Years: | 2% |
1 Year: | 39% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Dec 2023 | |
---|---|
Equity Capital | 23 |
Reserves | 992 |
19 | |
681 | |
Total Liabilities | 1,715 |
318 | |
CWIP | 13 |
Investments | 0 |
1,384 | |
Total Assets | 1,715 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Dec 2023 | |
---|---|
230 | |
38 | |
-878 | |
Net Cash Flow | -610 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Dec 2023 | |
---|---|
Debtor Days | 17 |
Inventory Days | 202 |
Days Payable | 89 |
Cash Conversion Cycle | 130 |
Working Capital Days | 25 |
ROCE % |
Documents
Announcements
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 17h
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 12 Apr
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
4 Apr - Copies of the newspaper publication related to notice of the Annual General Meeting, which will be held through video conferencing facility on 14th May 2024.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
4 Apr - Link Intime India Private Limited, Registrar and Share Transfer Agent (RTA) of the Company has provided the enclosed certificate for the quarter ended 31st March …
-
Announcement under Regulation 30 (LODR)-Resignation of Director
28 Mar - Mr. Marc-Antoine Lucchini (DIN: 08812302), Non-Executive Director, has vide his letter dated 28th March 2024, resigned from the Board of the Company, with effect from …
Annual reports
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2013
from nse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2010
from nse
Concalls
-
Feb 2024TranscriptPPT
-
Feb 2024Transcript PPT
-
Nov 2023TranscriptPPT
-
Nov 2023Transcript PPT
-
May 2023Transcript PPT
-
May 2023TranscriptPPT
-
Feb 2023TranscriptPPT
-
Feb 2023TranscriptPPT
-
Mar 2021TranscriptNotesPPT
India - Branded generics (79% of CY20 revenues):[1] Top-7 brands contribute ~70% of domestic sales and are growing at high single digits.[2]